Advertisement

Osteoporosis International

, Volume 27, Issue 4, pp 1469–1476 | Cite as

Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion

  • F. Chen
  • Z. DaiEmail author
  • Y. Kang
  • G. Lv
  • E. T. Keller
  • Y. Jiang
Original Article

Abstract

Summary

Treatment with zoledronic acid in osteoporotic patients with spinal fusion shortens the duration of time to fusion, improves the fusion rate, prevents the subsequent adjacent vertebral compression fractures, improves the clinical outcomes, and prevents immobilization-induced bone loss in the hip.

Introduction

The objective of the study was to explore the effects of zoledronic acid on the healing process in osteoporotic patients following spinal fusion in a randomized, placebo-controlled, and triple-blinded study.

Methods

Seventy-nine osteoporotic patients with single-level degenerative spondylolisthesis were randomly assigned to receive either zoledronic acid infusion (zoledronic acid group) or saline infusion (controls) after spinal fusion. Functional radiography and CT scans were used to evaluate fusion status. Bone formation was graded into three categories: Grade A (bridging bone bonding with adjacent vertebral bodies), Grade B (bridging bone bonding with either superior or inferior vertebral body), or Grade C (incomplete bony bridging). A solid fusion was defined as less than 5° of angular motion with Grade A or B bone formation. Adjacent vertebral compression fractures (VCF) were assessed on MRI at 12 months after surgery. Serum level of carboxy terminal cross-linked telopeptide of type I collagen (β-CTX) and amino-terminal propeptide of type I procollagen (PINP) was measured. Bone mineral density (BMD) was measured by DXA. Oswestry Disability Index (ODI) was used to assess the clinical outcomes.

Results

Grade A or B bridging bone was more frequently observed in zoledronic acid group at 3, 6, and 9 months post-operation compared to the control group (p < 0.05). At 12 -months post-operation, bridging bone and solid fusion were not significantly different between groups. No patients in zoledronic acid group showed aVCF, whereas six patients (17 %) in the control group did (p < 0.05). Both β-CTX and PINP were suppressed in zoledronic acid group. BMD at the femoral neck decreased rapidly and did not return to the preoperative level in the controls at 3 (−1.4 %), 6 (−2.5 %), and 12 (−0.8 %) months after surgery. Zoledronic acid prevented this immobilization-induced bone loss and increased BMD. ODI showed the improved clinical outcomes compared with controls at 9 and 12 months post-surgery.

Conclusion

Treatment with zoledronic acid in osteoporotic patients with spinal fusion shortens the time to fusion, improves the fusion rate, prevents subsequent aVCFs, and improves clinical outcomes.

Keywords

Bisphosphonates Posterior lumbar inter-body fusion Spinal fusion Zoledronic acid 

Notes

Acknowledgments

This research was supported by “the Fundamental Research Funds for the Central Universities” (2012QNZT148), Science and Technology Plan of Hunan Province (2012WK3039) and National Institutes of Health (P01 CA093900)

Compliance with ethical standards

The ethics committee of the Central South University approved the study.

Conflicts of interest

None

References

  1. 1.
    Etebar S, Cahill DW (1999) Risk factors for adjacent-segment failure following lumbar fixation with rigid instrumentation for degenerative instability. J Neurosurg 90(2 Suppl):163–169PubMedGoogle Scholar
  2. 2.
    Ponnusamy KE, Iyer S, Gupta G, Khanna AJ (2011) Instrumentation of the osteoporotic spine: biomechanical and clinical considerations. Spine J 11(1):54–63CrossRefPubMedGoogle Scholar
  3. 3.
    Guppy K, Paxton L, Harris J, Alvarez J, Bernbeck J (2014) Does bone morphogenic protein (BMP) change the operative nonunion rates in spine fusions? Spine (Phila Pa 1976) 39(22):1831–1839CrossRefGoogle Scholar
  4. 4.
    Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332(5):305–311CrossRefPubMedGoogle Scholar
  5. 5.
    Tella SH, Gallagher JC (2014) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142:155–170CrossRefPubMedGoogle Scholar
  6. 6.
    Dai Z, Dai R, Xiao Y et al (2010) Progress in anti-osteoporosis drug treatment. Chin J Osteoporos 16(11):894–906Google Scholar
  7. 7.
    Schimmer RC, Bauss F (2003) Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 25(1):19–34CrossRefPubMedGoogle Scholar
  8. 8.
    Zou X, Xue Q, Li H, Bünger M, Lind M, Bünge C (2003) Effect of alendronate on bone ingrowth into porous tantalum and carbon fiber interbody devices: an experimental study on spinal fusion in pigs. Acta Orthop Scand 74(5):596–603CrossRefPubMedGoogle Scholar
  9. 9.
    Xue Q, Li H, Zou X et al (2010) Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: an experimental study in a porcine model. Int Orthop 34(3):447–451CrossRefPubMedGoogle Scholar
  10. 10.
    Huang RC, Khan SN, Sandhu HS et al (2005) Alendronate inhibits spine fusion in a rat model. Spine 30(22):2516–2522CrossRefPubMedGoogle Scholar
  11. 11.
    Nagahama K, Kanayama M, Togawa D, Hashimoto T, Minami A (2011) Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. J Neurosurg Spine 14(4):500–507CrossRefPubMedGoogle Scholar
  12. 12.
    Recker RR, Delmas PD, Halse J et al (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23(1):6–16CrossRefPubMedGoogle Scholar
  13. 13.
    Seeman E, Martin TJ (2015) Co-administration of antiresorptive and anabolic agents: a missed opportunity. J Bone Miner Res 30(5):753–764CrossRefPubMedGoogle Scholar
  14. 14.
    Bransford R, Goergens E, Briody J et al (2007) Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur Spine J 16(4):557–562CrossRefPubMedGoogle Scholar
  15. 15.
    Fairbank JC, Pynsent PB (2000) The oswestry disability index. Spine 25(22):2940–2952CrossRefPubMedGoogle Scholar
  16. 16.
    Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733–759CrossRefPubMedGoogle Scholar
  17. 17.
    Gamsjaeger S, Buchinger B, Zwettler E et al (2011) Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res 26(1):12–18CrossRefPubMedGoogle Scholar
  18. 18.
    Bransford R, Goergens E, Briody J et al (2007) Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur Spine J 16(4):557–562CrossRefPubMedGoogle Scholar
  19. 19.
    Yalçin N, Öztürk A, Ozkan Y (2011) The effects of zoledronic acid and hyperbaric oxygen on posterior lumbar fusion in a rabbit model. J Bone Joint Surg Br 93(6):793–800CrossRefPubMedGoogle Scholar
  20. 20.
    Tu CW, Huang KF, Hsu HT et al (2014) Zoledronic acid infusion for lumbar interbody fusion in osteoporosis. J Surg Res 192(1):112–116CrossRefPubMedGoogle Scholar
  21. 21.
    Boonen S, Orwoll E, Magaziner J et al (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59(11):2084–2090CrossRefPubMedGoogle Scholar
  22. 22.
    Tamma R, Zallone A (2012) Osteoblast and osteoclast crosstalks: from OAF to Ephrin. Inflamm Allergy Drug Targets 11(3):196–200CrossRefPubMedGoogle Scholar
  23. 23.
    Ohtori S, Inoue G, Orita S et al (2013) Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine 38(8):E487–492CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2015

Authors and Affiliations

  • F. Chen
    • 1
  • Z. Dai
    • 1
    Email author
  • Y. Kang
    • 1
  • G. Lv
    • 1
  • E. T. Keller
    • 3
    • 4
    • 5
  • Y. Jiang
    • 2
    • 3
    • 5
  1. 1.Department of Spine Surgery, The 2nd Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.Osteoporosis and Arthritis LabUniversity of MichiganAnn ArborUSA
  3. 3.Department of UrologyUniversity of MichiganAnn ArborUSA
  4. 4.Biointerfaces InstituteUniversity of MichiganAnn ArborUSA
  5. 5.Comprehensive Cancer CenterUniversity of MichiganAnn ArborUSA

Personalised recommendations